This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Pick These 5 Profitable Stocks With Impressive Returns
by Gourav Kanti Bagchi
Profitability analysis helps in calculating the total expenses borne and total revenues generated by a company
Vertex's Cystic Fibrosis Drug Gets FDA Nod for Children
by Zacks Equity Research
Vertex's (VRTX) cystic fibrosis drug, Kalydeco gets FDA approval to treat children aged 12 months to two years
5 Sizzling Stocks Played Down by Hedge Funds in Q2
by Aniruddha Ganguly
We pick five large cap top-ranked stocks that have been ignored by hedge funds in Q2.
Ligand (LGND) Proposes to Buy U.K.'s Drug Discovery Biotech
by Zacks Equity Research
Ligand (LGND) makes an offer to acquire U.K.-based drug discovery biotech Vernalis to drive the same platform in its portfolio.
Ligand (LGND) Beats on Q2 Earnings & Revenues, Raises View
by Zacks Equity Research
Ligand (LGND) beats both earnings and sales estimates in the second quarter of 2018. The company raised its guidance for 2018.
Ligand Pharmaceuticals (LGND) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Ligand (LGND) delivered earnings and revenue surprises of 178.49% and 48.94%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
What Lies in Store for Ligand (LGND) This Earnings Season?
by Zacks Equity Research
Ligand's (LGND) Captisol formulation technology is expected to drive milestone and royalty payments in second-quarter 2018.
REGN vs. LGND: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
REGN vs. LGND: Which Stock Is the Better Value Option?
HZNP vs. LGND: Which Stock Is the Better Value Option?
by Zacks Equity Research
HZNP vs. LGND: Which Stock Is the Better Value Option?
3 Biotech Stocks Up in the Past Month on Industry Turnaround
by Zacks Equity Research
We take a look at three biotech stocks whose share price has increased in the past month due to as the biotech industry bounced back in the past month after declining in the initial four months of the year.
The Zacks Analyst Blog Highlights: Illumina, Athersys, EyePoint Pharmaceuticals, Rhythm Pharmaceuticals and Ligand Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Illumina, Athersys, EyePoint Pharmaceuticals, Rhythm Pharmaceuticals and Ligand Pharmaceuticals
Kitov (KTOV) Gets Approval from FDA for Consensi, Shares Up
by Zacks Equity Research
Kitov Pharma (KTOV) gained as the FDA approved Consensi (amlodipine and celecoxib) oral tablets for the treatment of osteoarthritis pain and hypertension.
"Right To Try" Brings Good News for Biotech Sector: 5 Picks
by Gourav Kanti Bagchi
Passage of the Right To Try law and WHO's focus on assessing the quality of bio-similar drugs is expected to benefit biotech stocks.
Catalyst's Fridapse Gets Priority Review by FDA, Shares Up
by Zacks Equity Research
The FDA grants Priority Review to Catalyst's (CPRX) lead pipeline candidate, Firdapse, and set an action date of Nov 28, 2018.
Allergan Recalls Taytulla Oral Contraceptives, Stock Down
by Zacks Equity Research
Allergan (AGN) recalls some sample packs of Taytulla oral birth control pills. Shares decline.
Bayer's Generic Competition, Pipeline Setback Issues Remain
by Zacks Equity Research
Generic threats/competition for many of its products remain a concern for Bayer (BAYRY).
Prothena Restructures Resources, to Cut Workforce by 57%
by Zacks Equity Research
Prothena announces a reduction in workforce by 57%, due to the discontinuation of lead program, NEOD001.
AbbVie's Imbruvica's Phase III Study Meets Primary Endpoint
by Zacks Equity Research
AbbVie's (ABBV) phase III iLLUMINA study evaluating Imbruvica in combination with Gazyva meets its primary endpoint of improvement in progression-free survival.
Agios (AGIO) Progressing Well on Pipeline Amid Competition
by Zacks Equity Research
Agios (AGIO) has several interesting candidates in its pipeline. However, the company still faces stiff competition.
SWTUY or LGND: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
SWTUY vs. LGND: Which Stock Is the Better Value Option?
Dr. Reddy's (RDY) Q4 Earnings Fall, Revenues Decline Y/Y
by Zacks Equity Research
Dr. Reddy's bottom line and top line suffered a year-over-year decline, in the fourth quarter of fiscal 2018.
Allergan Stock Down Since Q1 Earnings Report: Here's Why
by Zacks Equity Research
Though Allergan (AGN) boasts a solid underlying business, its stock is down. Here we discuss why.
Inovio Initiates Phase II Study on Pipeline Drug VGX-3100
by Zacks Equity Research
Inovio (INO) begins a phase II study to evaluate the efficacy of its pipeline candidate VGX-3100 on adult men and women with human papilloma virus (HPV)-related anal dysplasia.
AstraZeneca's Lokelma Gains FDA Nod to Treat Hyperkalemia
by Zacks Equity Research
AstraZeneca's (AZN) Lokelma secures an FDA approval for the treatment of hyperkalemia in adults.
Ligand Pharmaceuticals (LGND) Hits a 52-Week High, Can the Run Continue?
by Zacks Equity Research
Ligand Pharmaceuticals Incorporated is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for LGND for clues.